Rajen Dalal, president and CEO of Guava Technologies, has joined Ciphergen Biosystems’ board of directors. Bill Green, president and CEO of Stanford Research Systems, has resigned from the board of the company.
Following the acquisition of Semaia Pharmaceuticals by Hybrigenics (see p.1), Rian de Jonge, former CEO of Utrecht, the Netherlands-based Semaia, has become executive VP for research and development at Paris-based Hybrigenics.
Robert Weist has resigned from the board of directors of Camarillo, Calif.-based BioSource International for personal reasons.
Michael Dunn has been appointed to the newly created position of chief business officer of Mountain View, Calif.-based Aclara BioSciences. He joins the company from ActivX Biosciences, where he was executive vice president of business development. Previously, he was vice president of business development for Aurora Biosciences. Dunn holds an MBA from the University of San Diego and a BA in biology from the University of Chicago.
In addition, John Mendlein, chairman and CEO of Affinium Pharmaceuticals, has joined Aclara’s board of directors. Prior to Affinium, he was chief knowledge officer, general counsel, and senior vice president for intellectual property at Aurora Biosciences. Mendlein holds a PhD in biochemistry from UCLA and a JD from the UC Hastings College of Law.
Robert Strausberg, director of the NCI’s cancer genomics office, will become vice president for research at the Institute for Genomic Research (TIGR) on May 19.
David Ebsworth, CEO of Oxford GlycoSciences, has become a non-executive director of Italy-based Novuspharma. Prior to joining OGS, he was head of the worldwide pharmaceutical business group at Bayer.
Amy Romero-Gasman has been promoted to vice president for marketing, from senior director, at Exton, Pa.-based Adolor. Prior to joining the company in 2002, she was director of marketing at Oxford GlycoSciences. She holds a BA in biological psychology from the American University.